Literature DB >> 15955613

Mechanisms of neurotransmitter release by amphetamines: a review.

David Sulzer1, Mark S Sonders, Nathan W Poulsen, Aurelio Galli.   

Abstract

Amphetamine and substituted amphetamines, including methamphetamine, methylphenidate (Ritalin), methylenedioxymethamphetamine (ecstasy), and the herbs khat and ephedra, encompass the only widely administered class of drugs that predominantly release neurotransmitter, in this case principally catecholamines, by a non-exocytic mechanism. These drugs play important medicinal and social roles in many cultures, exert profound effects on mental function and behavior, and can produce neurodegeneration and addiction. Numerous questions remain regarding the unusual molecular mechanisms by which these compounds induce catecholamine release. We review current issues on the two apparent primary mechanisms--the redistribution of catecholamines from synaptic vesicles to the cytosol, and induction of reverse transport of transmitter through plasma membrane uptake carriers--and on additional drug effects that affect extracellular catecholamine levels, including uptake inhibition, effects on exocytosis, neurotransmitter synthesis, and metabolism.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15955613     DOI: 10.1016/j.pneurobio.2005.04.003

Source DB:  PubMed          Journal:  Prog Neurobiol        ISSN: 0301-0082            Impact factor:   11.685


  461 in total

1.  Differentiating the rapid actions of cocaine.

Authors:  Roy A Wise; Eugene A Kiyatkin
Journal:  Nat Rev Neurosci       Date:  2011-06-02       Impact factor: 34.870

2.  In vivo comparison of norepinephrine and dopamine release in rat brain by simultaneous measurements with fast-scan cyclic voltammetry.

Authors:  Jinwoo Park; Pavel Takmakov; R Mark Wightman
Journal:  J Neurochem       Date:  2011-10-20       Impact factor: 5.372

Review 3.  The solute carrier 6 family of transporters.

Authors:  Stefan Bröer; Ulrik Gether
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

Review 4.  Pharmacotherapeutics directed at deficiencies associated with cocaine dependence: focus on dopamine, norepinephrine and glutamate.

Authors:  Colin N Haile; James J Mahoney; Thomas F Newton; Richard De La Garza
Journal:  Pharmacol Ther       Date:  2012-01-31       Impact factor: 12.310

5.  Atypical dopamine transporter inhibitors attenuate compulsive-like methamphetamine self-administration in rats.

Authors:  Brendan J Tunstall; Chelsea P Ho; Jianjing Cao; Janaína C M Vendruscolo; Brooke E Schmeichel; Rachel D Slack; Gianluigi Tanda; Alexandra J Gadiano; Rana Rais; Barbara S Slusher; George F Koob; Amy H Newman; Leandro F Vendruscolo
Journal:  Neuropharmacology       Date:  2017-12-05       Impact factor: 5.250

6.  N-terminus regulation of VMAT2 mediates methamphetamine-stimulated efflux.

Authors:  B Torres; A E Ruoho
Journal:  Neuroscience       Date:  2013-12-07       Impact factor: 3.590

7.  Varenicline and GZ-793A differentially decrease methamphetamine self-administration under a multiple schedule of reinforcement in rats.

Authors:  Megan M Kangiser; Linda P Dwoskin; Guangrong Zheng; Peter A Crooks; Dustin J Stairs
Journal:  Behav Pharmacol       Date:  2018-02       Impact factor: 2.293

8.  Neuropsychiatric disease-associated genetic variants of the dopamine transporter display heterogeneous molecular phenotypes.

Authors:  Freja Herborg; Thorvald F Andreassen; Frida Berlin; Claus J Loland; Ulrik Gether
Journal:  J Biol Chem       Date:  2018-03-20       Impact factor: 5.157

9.  Development of serotonin transporter reuptake inhibition assays using JAR cells.

Authors:  Ann M Decker; Bruce E Blough
Journal:  J Pharmacol Toxicol Methods       Date:  2018-03-16       Impact factor: 1.950

10.  Characterization of the guinea pig animal model and subsequent comparison of the behavioral effects of selective dopaminergic drugs and methamphetamine.

Authors:  Kiera-Nicole Lee; Samuel T Pellom; Ericka Oliver; Sanika Chirwa
Journal:  Synapse       Date:  2014-01-31       Impact factor: 2.562

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.